Physician profile
Herman Benjamin Bell
NPI 1588789218
$15,438.29
in general payments reported to CMS, 2019-2025
36 companies · $4,004 in 2025
The $4,004 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.33 · 2020: $71.27 · 2021: $695 · 2022: $2,183 · 2023: $4,070 · 2024: $4,403 · 2025: $4,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $105 · Travel and Lodging: $6.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,365.84 |
| Education | $104.62 |
| Travel and Lodging | $6.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,547.91 | 2022-2025 | Otezla, Evenity, Enbrel |
| Otsuka America Pharmaceutical, INC. | $1,345.06 | 2021-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $1,122.45 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $1,112.61 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,000.23 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $961.89 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $863.51 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $811.91 | 2021-2025 | Jardiance, Tradjenta |
| Ibsa Pharma INC. | $731.03 | 2021-2025 | Licart, Tirosint, Licart |
| Lundbeck LLC | $572.18 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Sumitomo Pharma America, INC. | $475.55 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $435.12 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $364.41 | 2024-2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $278.51 | 2021-2023 | Linzess |
| Idorsia Pharmaceuticals US INC | $240.22 | 2023 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $205.83 | 2024 | Ibsrela |
| Mannkind Corporation | $186.53 | 2025 | |
| Axsome Therapeutics, INC. | $161.40 | 2024-2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $148.55 | 2023 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $136.75 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $122.39 | 2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $98.79 | 2021 | |
| Alkermes, INC. | $96.82 | 2019-2023 | Vivitrol |
| Angiodynamics, INC. | $82.98 | 2024-2025 | Auryon Laser System 100-120 Vac |
| Takeda Pharmaceuticals U.S.A., INC. | $67.80 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $67.10 | 2024-2025 | Zoryve |
| Boston Scientific Corporation | $39.82 | 2024 | |
| Novartis Pharmaceuticals Corporation | $26.40 | 2024 | |
| Eisai INC. | $25.75 | 2020 | |
| Merck Sharp & Dohme LLC | $18.81 | 2023 | Steglatro, Belsomra |
| Mylan Specialty L.P. | $17.76 | 2023 | Yupelri |
| Eyevance Pharmaceuticals LLC | $15.93 | 2021 | |
| Hikma Pharmaceuticals USA | $15.93 | 2021 | |
| Pfizer INC. | $14.42 | 2023 | |
| Scilex Pharmaceuticals INC. | $13.22 | 2024 | |
| Tactile Systems Technology INC | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herman Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.